Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Zealand Pharma is a Danish biotechnology company focused on peptide-based therapeutics for metabolic and gastrointestinal diseases. The company's lead commercial asset is Zegalogue (dasiglucagon) for severe hypoglycemia, with a pipeline including obesity and rare disease candidates. The stock trades on clinical trial outcomes, regulatory milestones, and partnership agreements with larger pharmaceutical companies for development and commercialization.
Zealand operates a hybrid model combining direct commercialization of niche products with strategic partnerships for larger market opportunities. The company leverages proprietary peptide engineering platforms to develop differentiated therapeutics, then monetizes through upfront payments, development milestones, regulatory approvals, and tiered royalties on partner sales. High gross margins (87.4%) reflect the specialty pharmaceutical pricing model, while negative operating margins indicate pre-profitability stage with significant R&D investment. The company's value proposition centers on peptide stability technology enabling subcutaneous delivery and improved pharmacokinetics versus traditional biologics.
Clinical trial readouts for pipeline candidates, particularly obesity and GLP-1 receptor agonist programs competing in the $50B+ metabolic disease market
Partnership announcements with major pharmaceutical companies including deal structures, upfront payments, and milestone potential
Regulatory decisions from FDA and EMA on New Drug Applications and label expansions for existing products
Quarterly Zegalogue prescription volume trends and market penetration in severe hypoglycemia indication
Cash runway updates and financing activities given $0.9B annual cash burn rate
Intensifying competition in GLP-1 and obesity therapeutic markets from Novo Nordisk (Wegovy/Ozempic), Eli Lilly (Mounjaro/Zepbound), and emerging oral peptide competitors potentially commoditizing the category
Regulatory pathway complexity for peptide therapeutics requiring extensive safety data, with FDA increasingly scrutinizing cardiovascular outcomes and long-term metabolic effects
Reimbursement pressure from payers limiting coverage for obesity medications and specialty diabetes products, particularly in European markets with government price controls
Pipeline dependency on differentiation versus established GLP-1 agonists requiring superior efficacy, safety, or convenience data to justify market share capture
Partnership concentration risk with revenue dependent on Boehringer Ingelheim and other collaborators' commercialization execution and strategic priorities
Small-cap biotech liquidity constraints limiting ability to compete with large pharmaceutical companies in clinical trial scale and speed-to-market
Significant cash burn ($0.9B annually) with current market cap of $4.4B creating potential dilution risk if additional equity financing required before profitability
Revenue volatility (-81.7% YoY) driven by lumpy milestone payments creating unpredictable cash flow timing and potential working capital strain
Limited commercial infrastructure for direct product launches requiring either partnership deals or substantial infrastructure investment reducing financial flexibility
low - Biotechnology companies developing treatments for chronic metabolic diseases and acute medical conditions exhibit minimal correlation to GDP cycles. Prescription demand for diabetes-related products and severe hypoglycemia treatments remains stable across economic environments. However, partnership activity and capital raising can be affected by risk appetite in biotech venture funding markets during recessions.
Rising interest rates create moderate headwinds through two channels: (1) Higher discount rates compress valuations of future cash flows from pipeline assets, particularly impactful for pre-revenue biotech with 5-10 year commercialization timelines; (2) Increased cost of capital for potential debt financing, though Zealand's 0.03 debt/equity ratio indicates minimal current leverage. The 14.10 current ratio provides substantial liquidity buffer reducing near-term financing pressure.
Minimal direct credit exposure. Zealand's business model does not involve significant accounts receivable risk given partnership-based revenues with investment-grade pharmaceutical counterparties. The company's ability to access capital markets for equity financing is more relevant than traditional credit conditions, though broader biotech sector sentiment affects valuation multiples.
growth - Attracts speculative biotech investors focused on binary clinical trial outcomes and partnership optionality rather than current fundamentals. The -1721% net margin and -$0.9B free cash flow indicate pure development-stage positioning. High volatility (evidenced by -42.7% one-year return and -21.9% three-month decline) appeals to risk-tolerant investors seeking asymmetric upside from successful drug approvals or acquisition premium. Not suitable for income or value investors given no dividends and negative earnings.
high - Biotechnology stocks exhibit elevated volatility driven by binary clinical trial outcomes, regulatory decisions, and partnership announcements creating 20-40% single-day moves. Zealand's small-cap status ($4.4B market cap) and limited float amplify price swings. The 54.9% ROE combined with negative margins suggests accounting volatility from milestone revenue recognition. Recent performance (-42.7% one-year, -21.9% three-month) reflects sector-wide biotech derating and company-specific clinical or commercial setbacks.
